Evidence map›Paper›PMID 41187808›Full record

ArticleJournal of advanced research2026

11-keto-β-boswellic acid and Z-guggulsterone suppress HMGB1/TLR4 pathway activity and modulate microglial polarization to remodel perineuronal nets after nerve injury.

Yucheng Liao, Le Yang, Yi Ding, Chao Guo, Junping Hu, Xinliang Xu, Hui Zhu, Jianhua Yang, Minggao Zhao

Abstract read
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Epitranscriptomic sculpting: the role of mMedical oncology (Northwood, London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yucheng LiaoPrecision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Le YangPrecision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China; State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
Yi DingDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Chao GuoDepartment of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Junping HuSchool of Pharmacy, Xinjiang Medical University, Urumqi, China.
Xinliang XuDepartment of Pain, Jining No.1 Peoples Hospital, Jining, China.
Hui ZhuState Key Laboratory for Manufacturing System Engineering, Xi'an Jiaotong University, Xi'an, China. Electronic address: hui.zhu@xjtu.edu.cn.
Jianhua YangDepartment of Pharmacy, The First Affiliated Hospital, Xinjiang Medical University, Urumqi, China; Xinjiang Key Laboratory of Clinical Drug Research, Urumqi, China. Electronic address: yjh-yft@163.com.
Minggao ZhaoPrecision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China. Electronic address: minggao@fmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRemodeling of perineuronal nets is an emerging strategy for treating neuropathic pain (NP) and aligns with the traditional Chinese medicine concept of dispersing blood stasis dispersion and dredging collateral channels. Frankincense and myrrh are known for their ability to promote blood circulation, eliminate blood stasis, unblock collateral channels, and relieve pain. However, the precise pharmacological components and mechanisms underlying their analgesic effects remain unclear.

objectivesThis study aimed to clarify the mechanisms of action of 11-keto-β-boswellic acid (KBA, a component of frankincense) and Z-Guggulsterone (Z-GS, a component of myrrh) in remodeling perineuronal nets.

methodsAn NP model was developed via sciatic nerve chronic constriction injury (CCI), and possible targets and pathways were identified through transcriptomic analysis. To assess the effects of blocking the HMGB1/TLR4 signaling pathway on NP, the HMGB1 inhibitor BoxA and the TLR4 antagonist LRU were administered intrathecally. Additionally, KBA and Z-GS were administered via intraperitoneal injection for 14 days. The influence of KBA and Z-GS on perineuronal net remodeling via microglia polarization through HMGB1/TLR4 signaling was then investigated.

resultsTranscriptomic analysis suggested that HMGB1/TLR4-induced neuroinflammation may play a role in NP. Intrathecal BoxA and LRU administration significantly decreased mechanical and thermal pain sensitivity levels in CCI mice, promoted microglia polarization by modulating neuroinflammation, and reversed perineuronal net degradation. Further analyses revealed that combining KBA and Z-GS resulted in a more pronounced reduction in mechanical and thermal pain sensitivities, downregulation of HMGB1, TLR4, MyD88, p-P65, and TRPV1 in microglia of the spinal dorsal horn, and enhanced microglia polarization, ultimately facilitating perineuronal net remodeling.

conclusionKBA and Z-GS alleviate NP in a combined effects, likely through inhibition of the HMGB1/TLR4 signaling pathway, which regulates microglia polarization and promotes perineuronal net remodeling. This suggests that targeting HMGB1/TLR4 signaling may be a promising means of treating NP.

Indexed as

HMGB1 ProteinMicrogliaNeuralgiaPregnenedionesToll-Like Receptor 4TriterpenesAnimalsDisease Models, AnimalMaleMiceSciatic NerveSignal TransductionHMGB1 ProteinHMGB1 protein, mousePregnenedionesTlr4 protein, mouseToll-Like Receptor 4TriterpenesHMGB1/TLR4 pathwayMicrogliaNerve injuryNeuropathic painPerineuronal nets

Identifiers

PMID41187808
PMCPMC13316438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.